We are committed to addressing the global health threat posed by superbugs through pioneering a new class of synthetic antibiotics to treat serious and life threatening bacterial and antibiotic resistant infections. Our approach to treating bacterial infections has the potential to transform the current antibiotic business model .
Recce’s synthetic polymer antibiotics have a universal mechanism of action that allow its compounds to overcome antibiotic resistance. They are designed to empower physicians with a potent treatment that can be used repeatedly against a broad range of bacteria without contributing to antibiotic resistance.
We have invested in establishing scalable infrastructure and manufacturing capabilities ensuring our facility is equipped to produce RECCE products in volumes to support planned Phase I and II human clinical trials whilst de-risking the expansion beyond.
Investment has also been made in establishing strong management and regulatory expertise needed to support our clinical and regulatory pathway towards product approval.
We seek to leverage the ever-increasing global incentives to encourage the development of new antibiotics. The U.S Food and Drug Administration (FDA) awarded Recce Qualified Infectious Disease Product (QIDP) designation under the Generating Antibiotic Initiatives Now (GAIN) Act emphasising the potential of our lead candidate, RECCE® 327.
This designation fast tracks RECCE® 327 through the regulatory review process so it can be available to treat patients with serious or life-threatening conditions sooner. Additionally, RECCE® 327 has been given rights to be used in Australia as a last resort for patients with sepsis under the Therapeutic Goods Administration (TGA) Special Access Scheme – Category A.
Our strategy is further supported by our extensive and wholly owned patent and intellectual property portfolio covering composition of matter, manufacturing, and therapeutic applications. We use raw materials which are in plenty and inexpensive adding to the capability to scale up production quickly and cost-effectively.
Recce’s patent portfolio includes more than 15 issued patents and patent applications in the world’s major markets, including the United States, Europe, Japan, China and Australia.